Erratum to: Genomics-Guided Precise Anti-Epileptic Drug Development
نویسندگان
چکیده
منابع مشابه
Anti-epileptic drug harms: issues for meta-analysis
Objectives Decisions regarding choice and dose of anti-epileptic drug (AED) are driven by considering the potential benefits of reducing seizure frequency against the potential harms of alternative AEDs. Such decisions should be made using the best available evidence, which often requires a quantitative synthesis of data from multiple randomised controlled trials (RCT). However, the systematic ...
متن کاملAccelerating Drug Discovery and Development Using Genomics
Despite the continuing advancements in the treatment of cancer and the introduction of new therapies, responses still vary from patient to patient. In many cases, this variation remains unexplained, making it difficult to predict who will respond. For instance, immunotherapies targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and the PD-1 li...
متن کاملNewer anti-epileptic drugs.
NEED AND PURPOSE OF REVIEW A number of newer anti-epileptic drugs have been developed in the last few years to improve the treatment outcomes in epilepsy. In this review, we discuss the use of newer anti-epileptic drugs in children. METHODS USED FOR LOCATING, SELECTING, EXTRACTING AND SYNTHESIZING DATA MEDLINE search (1966-2013) was performed using terms newer anti-epileptic drugs, Oxcarbazep...
متن کاملNew anti-epileptic drugs.
Epilepsy represents the most common serious neurological disorder, with a prevalence of 0.4 - 1%. Approximately 30% of patients are resistant to currently available drugs. New anti-epileptic drugs are needed to treat refractory epilepsy, improve upon current therapies, improve the prognosis of epilepsy and to prevent the epileptogenic process. Designing compounds with specific physiological tar...
متن کاملTargeting anti-epileptic drug therapy without collateral damage: nanocarrier-based drug delivery.
Commentary Medically refractory epilepsy is estimated to occur in about 500,000 individuals of the nearly 3 million in the United States with epilepsy. Medication resistance in epilepsy is due, in part, to tolerance related to molecular mechanisms that eliminate, or minimize the persistence of antiepileptic drug (AED) molecules in the brain. Currently, drug discovery for CNS disorders is almost...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurochemical Research
سال: 2017
ISSN: 0364-3190,1573-6903
DOI: 10.1007/s11064-017-2396-4